Investment
Features
FeesSafety
Academy
More
Pluang+

Compare State Street SPDR Bloomberg 1-3 Month T-Bill ETF (BIL) vs Hims and Hers Health Inc (HIMS) Price & Performance

State Street SPDR Bloomberg 1-3 Month T-Bill ETFTrade
Hims and Hers Health IncTrade

Price performance (Past 24H)

Key statistics

State Street SPDR Bloomberg 1-3 Month T-Bill ETF vs Hims and Hers Health Inc — how do they compare? State Street SPDR Bloomberg 1-3 Month T-Bill ETF trades at $91.49, while Hims and Hers Health Inc trades at $30.55 (market cap $7.35B). The key difference: State Street SPDR Bloomberg 1-3 Month T-Bill ETF is trading nearer its 52-week high, Hims and Hers Health Inc nearer its low. Which is the better fit depends on your goals.

BILHIMS
Sector
Fixed IncomeHealth
52-Week High
$91.77$62.76
52-Week Low
$91.27$14.52
Market Cap
$7.35B
Enterprise Value
$7.73B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

State Street SPDR Bloomberg 1-3 Month T-Bill ETF

BIL trades at $91.48 with minimal daily movement (+0.03%), showing stability amid market volatility. The ETF maintains consistent dividend distributions of $0.27 per share quarterly, with recent institutional buying activity indicating professional confidence. Technical indicators show bearish momentum with moving averages signaling caution, though oscillators suggest potential stabilization near current levels.

As a short-term Treasury ETF, BIL offers capital preservation and steady income through Treasury bill exposure. Key risks include interest rate sensitivity and inflation pressures affecting Treasury yields. The fund's defensive positioning appeals to risk-averse investors seeking liquidity and minimal credit risk in uncertain markets.

Hims and Hers Health Inc

Hims & Hers Health stock trades at $31.59, up 6.51% today, showing strong momentum. The technical outlook is bullish, with the price above key moving averages and support at $30. Fundamentally, revenue growth is robust at 40% year-over-year in Q2 2026 (MarketBeat, 2026-08-10), but profitability remains challenged with a net loss margin of -0.56% in 2026. The company raised its annual revenue forecast to $3.1–3.3 billion (WSJ, 2026-08-10), reflecting confidence in subscriber growth and expansion into weight-loss treatments.

The investment outlook is mixed: strong revenue growth and bullish analyst targets near $35.60 offer upside, but high valuation ratios (P/E of 57.14) and recent earnings misses heighten risk. Key risks include margin pressure from GLP-1 investments and ongoing legal investigations. Wall Street sentiment is cautious, with 65% hold ratings, suggesting patience for profitability improvements.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About State Street SPDR Bloomberg 1-3 Month T-Bill ETF

BIL tracks the performance of short-term U.S. Treasury bills with maturities between 1 and 3 months. It is designed for investors seeking a highly liquid, low-risk vehicle for cash management and capital preservation.

Read more on BIL

About Hims and Hers Health Inc

Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.

Read more on HIMS